lost
23 stories and discussions about lost, aggregated from every source we track.
Is this really the Solar System’s first rodeo?
Food news and dining guides for New York City.
Obesity may leave behind a cellular memory that pushes the body to regain lost weight.
Is this really the Solar System’s first rodeo?
Here’s a theory you hear a lot these days: “Microsoft is finished. As soon as Linux makes some inroads on the desktop and web applications replace desktop applications, the mighty empir…
Knight Capital, August 1, 2012: new code reached 7 of 8 servers, a reused feature flag woke dead code on the 8th, and it lost $460 million in 45 minutes.
Kernal Fit: how one IT professional lost the desk-job weight with small changes to eating habits. No gym, no heavy dieting. $9 ebook.
By 40, ~79% of Americans have lost someone they know to a crash. Most would trade faster driving for safer streets if someone asked them.
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
By 40, ~79% of Americans have lost someone they know to a crash. Most would trade faster driving for safer streets if someone asked them.
rm -rf on the wrong host: in 2017 a GitLab engineer wiped the production PostgreSQL database, and none of the five backups worked. The full postmortem.
It has been a difficult time for me since I lost some friends due to not gaming. They did not understand that I couldn't afford the latest game at the time. ...
The Epigraphic Survey of the Oriental Institute of the University of Chicago produced a series of limited-edition photographs titled Lost Egypt. These exquisite photographic prints recapture images of
A pastor and his wife created a cryptocurrency and hawked it in Christian communities. When it came crashing down, investors lost millions―and they were accused of fraud.
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations. Patients with obesity on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks, and an average of 30 percent after an extension period to 104 weeks. Overall, more than a third of participants taking retatrutide lost 30 percent or more of their weight. The drug also proved effective at reducing knee pain (by up to 62 percent) in a subset of participants with obesity-linked knee osteoarthritis. It reduced the number of sleep apnea events per hour (by up to 57 percent) in a subset of participants with obesity-linked obstructive sleep apnea. The drug improved cardiometabolic measurements across the board, including blood pressure, triglycerides, and low-density lipoprotein cholesterol (bad cholesterol). At the start, more than a third of trial participants had prediabetes and, by the end, the condition had resolved in more than 90 percent of those participants. The trial began in 2023 and included 2,339 participants from 131 clinical trial sites in 11 countries. Participants were broken into four nearly equal groups, given either: 4 mg of retatrutide, 9 mg, 12 mg, or a placebo. Across all groups, the average starting weight was around 113 kg (250 pounds), and the average body mass index (BMI) was 40. For the subset analyses, 574 participants had knee osteoarthritis, and 243 had obstructive sleep apnea. The results appeared today in the New England Journal of Medicine . Read full article Comments